Abstract 182P
Background
Gastric adenocarcinoma (GA) with peritoneal carcinomatosis is associated with poor prognosis with median overall survival surfacing under the one-year mark. The treatment of gastric cancer remains controversial. Using hyperthermic intraperitoneal chemotherapy (HIPEC) in combination with cytoreductive surgery may help reduce mortality rates. This study attempted to investigate treatment modalities available for metastatic gastric adenocarcinoma.
Methods
We extracted all adult patients with intestinal-type gastric adenocarcinoma with 7th edition AJCC M1 stage (2010-2015) using the Surveillance Epidemiology and End Results (SEER) database. Patients with extra-peritoneal metastasis were excluded. We stratified patients into four different groups: surgery, chemotherapy, surgery and chemotherapy, and no surgery/no chemotherapy. Kaplan-Meier and Cox proportional hazard regression models were utilized to access overall survival (OS) and cancer-specific survival (CSS).
Results
A total of 243 patients were identified. The median (OS) of the entire cohort was 11 months. Patients who received both chemotherapy and surgery, chemotherapy alone, and surgery alone had higher median (OS) compared to no treatment [19, 13, and 6 months, respectively, vs 3 months, p<0.001], as well as a higher (CSS) (p<0.0001). Patients who received no therapy had a statistically significant risk of overall mortality compared to the chemotherapy and surgery group [HR= 9.28 (5.40 -15.94). p<0.001], and compared to other treatment groups (p<0.001). N3B Stage was a significant risk factor for (OS) and (CSS) [HR= 2.69 (1.23 -5.78), p<0.013]. Table: 182P
Median overall survival
N | Events | Median survival | 95% CI | |
Overall Survival (OS) | ||||
No treatment administered | 56 | 54 | 3 | (2- 5) |
Chemotherapy alone | 91 | 86 | 13 | (11- 17) |
Surgery alone | 32 | 29 | 6 | (3- 16) |
Both chemotherapy and surgery | 64 | 55 | 19 | (16- 29) |
Cancer-Specific Survival (CSS) | ||||
No treatment administered | 56 | 53 | 3 | (2- 5) |
Chemotherapy alone | 87 | 75 | 13 | (11-18) |
Surgery alone | 30 | 21 | 15 | (4-43) |
Both chemotherapy and surgery | 62 | 49 | 19 | (16-31) |
Conclusions
The combined usage of surgery and chemotherapy significantly improved the median overall and cancer-specific survival for (GA) patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
251P - LDH isozyme as a prognostic factor for patients with metastatic clear cell renal cell carcinoma (mCRCC)
Presenter: Hayato Takeda
Session: Poster Display
Resources:
Abstract
252P - Risk factors for recurrence after curative nephrectomy in non-metastatic renal cell carcinoma: A retrospective cohort study
Presenter: Kristine Tejada
Session: Poster Display
Resources:
Abstract
253TiP - WUTSUP-02-II-Neo-Dis-Tis: Investigating the efficacy and safety of neoadjuvant tislelizumab plus disitamab vedotin with adjuvant tislelizumab in upper urinary tract carcinoma: A phase II multi-center study
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
254TiP - Prospective observational trial of cabozantinib plus nivolumab in Japanese patients with advanced or metastatic renal cell carcinoma: JACUMET trial
Presenter: Yuji Miura
Session: Poster Display
Resources:
Abstract
264P - Interim results from a phase I study of AMG 509 (xaluritamig), a STEAP1 x CD3 XmAb 2+1 immune therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Chia-Chi Lin
Session: Poster Display
Resources:
Abstract
266P - Clinical application and potential impact of liquid biopsy on the management of Chinese patients with metastatic castration-resistant prostate cancer (mCRPC): A territory-wide prospective analysis
Presenter: Wai Kay Philip Kwong
Session: Poster Display
Resources:
Abstract
267P - Exploring homologous recombination deficiency threshold for predicting response to PARP inhibitor in prostate cancer
Presenter: Diwei Zhao
Session: Poster Display
Resources:
Abstract
268P - Comparisons of on new-onset prostate cancer in type 2 diabetes mellitus exposed to the SGLT2I and DPP4I: A population-based cohort study
Presenter: Hou In Chou
Session: Poster Display
Resources:
Abstract
269P - Prostate cancer harboring low COMT expression correlates with a poor prognosis and response to enzalutamide
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract
270P - Germline BRCA1/2 pathogenic variants in Japanese patients with prostate cancer are predictive factors for androgen receptor-axis-targeted therapy or chemotherapy for castration-resistant prostate cancer
Presenter: Shigekatsu Maekawa
Session: Poster Display
Resources:
Abstract